ST. LOUIS, Feb. 9, 2012 /PRNewswire/ -- K-V Pharmaceutical Company (the "Company") (NYSE: KVa/KVb) today reported updated performance metrics for Makena®.
Makena® was launched during March of 2011. From its launch date through January 31, 2012:
- Approximately 7,900 vials have been shipped to Ther-Rx customers of which approximately 6,500 vials have been distributed to doctors and patients. This is an increase of approximately 600 vials shipped to customers and 1,600 vials shipped to doctors and patients since November 2011;
- As part of Ther-Rx's commitment to patient access, we have also provided approximately 1,200 additional vials at little or no patient out-of-pocket cost through our patient assistance program for use by patients who have demonstrated financial need;
- Approximately 6,000 patient referrals from over 3,500 prescribers have been made to the Makena Care Connection®, an increase of approximately 1,200 patients and 500 prescribers since November 2011;
- Approximately 3,700 patients have either initiated treatment, are in the enrollment phase or are pending insurance approval and treatment initiation, an increase of more than 900 patients since November 2011;
- Over 250 payers, both commercial and Medicaid, have reimbursed Makena® and at least 19 states have reimbursed Makena®; and
- Current data indicates patient co-pays are averaging approximately $10 per injection, the same or less cost than those typically associated with compounded 17P formulations.
"We continue to advance our commercialization strategy for Makena® by actively engaging the medical and payer communities on the differences between FDA-approved Makena® and unapproved compounded 17P formulations," said Greg Divis, President and CEO of K-V Pharmaceutical and President of Ther-Rx. "Our efforts are driving improved performance metrics and we are intensely focused on continuing to grow our market share."
Fiscal 2012 Form 10-Q and Investor Conference Call
The Company will be filing its fiscal 2012 third quarter Form 10-Q with the U.S. Securities & Exchange Commission (SEC) after the close of market today. The Company will host an investor conference call on Friday, February 10, 2012 at 8:30 a.m. EST to discuss the information contained in the Form 10-Q as well as provide a general update on other company matters. Participants can listen to the conference call by dialing 866-843-0890 and providing code 4088697. To access the live web cast of the conference call, please go to the investor relations portion of the Company's website under "Conference Calls" at www.kvpharmaceutical.com. Please log-in or dial-in at least 10 minutes prior to the start time to ensure a connection.
A replay of the call will also be available for seven days by calling 877-344-7529 and providing code 10009958. An archived version of the webcast will be accessible for 30 days at www.kvpharmaceutical.com.
About K-V Pharmaceutical Company
K-V Pharmaceutical Company is a specialty branded pharmaceutical company with a primary focus in the area of women's healthcare. As such, we are committed to advancing the health of women across all the stages of their lives.
